MET and cholangiocarcinoma: There are currently an abundance of clinical trials studying selective and nonselective c-MET inhibitors alone or in combination with other therapies across many cancers with MET mutations or amplification.17 There are currently no ongoing clinical trials specifically targeting c-MET positive CCA, though these patients may be eligible to enter any trial investigating these agents in all solid tumors.